AstraZeneca, Ranbaxy prevail in Nexium antitrust trial
The US Federal Trade Commission estimates that pay-for-delay deals, in which a branded drugmaker pays a generic rival to stay off the market, cost consumers $3.5 billion each year.
Dec 06, 2014, 08:43 AM IST
US denies Ranbaxy's bid to block launch of rival generics
A US court has denied a request by drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc`s heartburn pill Nexium and Roche`s antiviral, a court filing showed.
Nov 20, 2014, 21:58 PM IST
Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies
Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the firm to launch copies of two drugs including AstraZeneca Plc`s heartburn pill Nexium, court documents showed.
Nov 18, 2014, 15:35 PM IST
